Primary Objective: To determine the rate of downstaging to resectability in patients with
borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative
therapy.
Secondary Objective(s):
1. To assess the disease-free-survival, overall survival, time to recurrence and site of
recurrence in patients with borderline resectable pancreatic cancer receiving
preoperative FOLFIRINOX followed by SBRT
2. To investigate the safety and tolerability of FOLFIRINOX and SBRT in patients with
resectable pancreatic cancer
3. To determine the radiologic and pathological response associated with preoperative SBRT
and FOLFIRINOX therapy
4. To assess quality of life through and after treatment using the FACT-Hep questionnaire
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore